A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.


OBJECTIVES This paper aims to investigate the efficacy of intravenous immunoglobulin (IVIG) for skin sclerosis in diffuse cutaneous systemic sclerosis (dcSSc) by a randomised, double-blind, placebo-controlled, multicentre trial (DBT) with subsequent long-term observational and readministration studies. METHODS In DBT, IVIG (400mg/kg/day for 5 consecutive… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.